CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

Abstract CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority of CAR T-treated patients will eventually progress and require salvage treatment, for which there is no current...

Full description

Bibliographic Details
Main Authors: Yun Liang, Hui Liu, Zheming Lu, Wen Lei, Chaoting Zhang, Ping Li, Aibin Liang, Ken H. Young, Wenbin Qian
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Journal of Hematology & Oncology
Subjects:
DLBCL
CAR T cell therapy
PD-1/CD28 chimeric switch receptor
Salvage therapy
Online Access:https://doi.org/10.1186/s13045-021-01044-y

Internet

https://doi.org/10.1186/s13045-021-01044-y

Similar Items